La cadena de opciones muestra datos clave de las opciones de acciones de Journey Medical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Journey Medical..

Journey Medical (NASDAQ:DERM) Bolsa, Cadena de Opciones

Journey Medical

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ALMS

CMRX

DERM

Alumis, Chimerix y Journey Medical presentan altos valores RSI, lo que podría señalar sobrecompra. ¿Es este el momento adecuado para invertir?

¿Deberías preocuparnos por estas 3 acciones del sector salud? El RSI indica sobrecompra

Journey Medical Corporation - Common Stock

Journey Medical Corp

DermTech Inc

DermTech Inc Warrants(20/06/2022)

Dermapharm Holding SE

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

Dermisonics Inc

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Alumis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>)</h3>
<ul>
<li>On March 25, Alumis, Inc announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals. Under the agreement, Alumis is licensing ESK-001, a drug aimed at treating immune dysregulation in various diseases, to Kaken for development, manufacturing and commercialization in Japan, limited to dermatologic applications.. The company's stock gained around 106% over the past month and has a 52-week high of $13.50.</li>
<li>RSI Value: 77.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ALMS Price Action: Shares of Alumis gained 17.7% to close at $10.05 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Chimerix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>)</h3>
<ul>
<li>On March 21, Chimerix reported quarterly losses of 25 cents per share which beat the analyst consensus estimate of a loss of 26 cents per share. The company reported quarterly sales of $57.00 thousand which missed the analyst consensus estimate of $75.00 thousand by 24.00 percent. The company's stock gained around 837% over the past six months and <a href="https://www.benzinga.com/quote/CMRX">has a 52-week high</a> of $8.54.</li>
<li>RSI Value: 82.7</li>
<li>CMRX Price Action: Shares of Chimerix closed at $8.53 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Journey Medical Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>)</h3>
<ul>
<li>On April 1, Journey Medical Corporation named Ramsey Alloush as Chief Operating Officer. Claude Maraoui, President and Chief Executive Officer of Journey Medical, said, &#8220;Ramsey&#8217;s promotion to COO reflects his exceptional leadership and the critical role he has played in our Company&#8217;s growth. His deep understanding of our business and the industry uniquely positions him to drive our strategic initiatives forward, focusing on operational excellence and maximizing shareholder value.&#8221; The company's stock gained around 40% over the past month and has a 5<a href="https://www.benzinga.com/quote/DERM">2-week high</a> of $7.29.</li>
<li>RSI Value: 77.3</li>
<li>DERM Price Action: Shares of Journey Medical gained 9.1% to close at $7.19 on Friday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Top 3 Health Care Stocks That May Crash In Q2

Alloush Will Continue To Also Serve As The Company's General Counsel.

Management

Journey Medical Promotes Ramsey Alloush, Currently General Counsel, To The Position Of COO

<h3>Companies Reporting Before The Bell</h3>
• Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is estimated to report quarterly loss at $5.00 per share on revenue of $5.60 million. 
• Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is projected to report quarterly earnings at $2.18 per share on revenue of $8.23 billion. 
• Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $3.20 billion. 
• Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $384.72 million. 
• Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.60 billion. 
• SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) is expected to report quarterly loss at $0.03 per share on revenue of $202.71 million. 
• REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $152.00 million. 
• CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $358 thousand. 
• Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $80.10 million. 
• JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) is estimated to report quarterly loss at $0.46 per share on revenue of $3.59 billion. 
• BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $1.35 billion. 
• Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $88.50 million. 
• Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is expected to report quarterly loss at $2.94 per share on revenue of $4.28 million. 
• Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) is expected to report earnings for its fourth quarter. 
• Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is projected to report quarterly earnings at $1.48 per share on revenue of $1.51 billion. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) is estimated to report earnings for its fourth quarter. 
• Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) is likely to report earnings for its fourth quarter. 
• TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) is likely to report earnings for its fourth quarter. 
• Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $40.63 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is projected to report quarterly loss at $0.11 per share on revenue of $114.96 million. 
• BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is projected to report quarterly loss at $0.87 per share on revenue of $20 thousand. 
• Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is projected to report earnings for its fourth quarter. 
• Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $6.91 million. 
• Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $14.21 million. 
• Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is expected to report earnings for its fourth quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $33.09 million. 
• Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is projected to report quarterly earnings at $1.13 per share on revenue of $1.97 billion. 
• Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $2.10 million. 
• H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $797.68 million. 
• Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is expected to report quarterly loss at $0.06 per share on revenue of $1.35 million. 
• Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $21.40 million. 
• Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $276.82 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $3.01 per share on revenue of $2.47 billion. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is projected to report earnings for its fourth quarter. 
• Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $790.90 million. 
• Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $320.52 million. 
• Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) is expected to report quarterly loss at $0.26 per share on revenue of $232 thousand. 
• MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $918.88 million. 
• Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $87.50 million. 
• Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $1.56 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ALUR

ALVO

BCDA

CATX

CHWY

CLGN

CMCM

CNXC

CTAS

DLTR

DOOO

DRRX

DTIL

DYAI

GRDN

ITRG

MLKN

MVIS

OXBR

PAYX

SAIL

SNAL

Spruce Power Holding Corporation Class A Common Stock

SPRU

TATT

TTAM

USIO

VRNT

WOOF

ZEPP

Earnings Scheduled For March 26, 2025

DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks
Published data from two Phase 3 clinical trials demonstrated statistical superiority of DFD-29 over both Oracea&#xAE;&nbsp;(doxycycline) capsules and placebo for IGA treatment success and the reduction of total lesion count, as well as significantly superior reduction in erythema compared to placebo in both studies
U.S. FDA approved Emrosi&#x2122; (also known as DFD-29) for the treatment of inflammatory lesions of rosacea in adults in November 2024; launch expected in early spring of 2025
SCOTTSDALE, Ariz., March 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that full results from two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, Minocycline Versus Oracea&#xAE; in Rosacea-1 ("MVOR-1") and Minocycline Versus Oracea in Rosacea-2 ("MVOR-2"), evaluating Minocycline Hydrochloride Extended Release Capsules, 40 mg ("DFD-29" or "Emrosi") for the treatment of moderate-to-severe papulopustular rosacea in adults were published in the Journal of the American Medical Association - Dermatology ("JAMA Dermatology"). The results demonstrated the efficacy, safety and tolerability of oral DFD-29 in rosacea. Read the full publication here: <a href="https://www.globenewswire.com/Tracker?data=IQdcOCvkQy_om0z2ylvmrLZvuKwN_lqXU9gCO2NkphJvMndfr31QK9hYRaVC98MD9ELN95UcKRHs-hFxotfbcpH8nTC5_WhywP2ePZ6su2vfm6DEAD7h6POklP8XJYbe4t2Pdtb_s_QZf9Tq3Iau4Q==">JAMA</a>.
The FDA approved Emrosi&#x2122; for the treatment of inflammatory lesions of rosacea in adults in November 2024.

Biotech

General

Journey Medical Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi To Treat Rosacea; DFD-29 Achieved The Co-Primary And All Secondary Endpoints With No Significant Safety Issues When Administered Once Daily For 16 Weeks

<h3>Gainers</h3>
<ul>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares rose 26.9% to $3.82 during Friday's pre-market session. The market value of their outstanding shares is at $186.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock increased by 19.74% to $0.39. The market value of their outstanding shares is at $6.4 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock rose 17.01% to $0.78. The company's market cap stands at $48.1 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock rose 14.44% to $1.03. The market value of their outstanding shares is at $4.6 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock increased by 12.84% to $1.23. The market value of their outstanding shares is at $10.7 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) shares rose 11.76% to $0.95. The company's market cap stands at $62.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) stock fell 74.5% to $2.19 during Friday's pre-market session. The market value of their outstanding shares is at $254.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock declined by 13.52% to $4.8. The market value of their outstanding shares is at $100.2 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 12.64% to $7.05. The company's market cap stands at $4.7 billion. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock fell 12.38% to $4.25. The company's market cap stands at $47.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock declined by 10.37% to $0.54. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 9.96% to $1.9. The company's market cap stands at $191.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLT

ARAY

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BMRA

CABA

GRFS

IOBT

NTRB

PASG

SILO

TCBP

12 Health Care Stocks Moving In Friday's Pre-Market Session

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 115 percent decrease over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $14.63 million which beat the analyst consensus estimate of $14.39 million by 1.68 percent. This is a 57.64 percent decrease over sales of $34.54 million the same period last year.

Earnings Beats

Journey Medical Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $14.63M Beat $14.39M Estimate

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 127.9% to $3.1 during Monday's regular session. The company's market cap stands at $5.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) stock moved upwards by 58.24% to $21.3. The company's market cap stands at $53.1 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 44.04% to $66.36. The market value of their outstanding shares is at $862.2 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock rose 24.27% to $23.96. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 23.42% to $1.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares moved upwards by 22.19% to $57.59. The market value of their outstanding shares is at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 15.8% to $1.98 during Monday's regular session. The company's market cap stands at $10.7 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock declined by 15.6% to $7.12. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares declined by 15.57% to $12.1. The market value of their outstanding shares is at $497.2 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares decreased by 15.52% to $14.87. The market value of their outstanding shares is at $22.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 13.5% to $2.05. The company's market cap stands at $349.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock decreased by 13.3% to $5.35. The market value of their outstanding shares is at $110.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCRX

BSGM

CVKD

IART

IRON

NGNE

NUWE

OMIC

THRD

TVGN

XTLB

12 Health Care Stocks Moving In Monday's Intraday Session

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the <a href="https://www.benzinga.com/pressreleases/24/11/g41709594/journey-medical-corporation-announces-u-s-fda-approval-of-emrosi-minocycline-hydrochloride-extende">treatment of rosacea</a>.
What Happened: The FDA has approved Journey Medical&#8217;s Emrosi, formerly known as DFD-29, for the treatment of inflammatory lesions of rosacea in adults.&nbsp;
The approval was supported by positive data from the company&#8217;s two Phase 3 clinical trials, which met all co-primary and secondary endpoints. Journey Medical said Emrosi demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea, and placebo. 
Journey Medical announced that it&#8217;s in the process of completing the manufacturing of Emrosi for the U.S. market. The company expects initial supply of the drug to be available late in the&nbsp;first quarter&nbsp;or early in the&nbsp;second quarter&nbsp;of 2025.
&#8220;With approval from the FDA, Journey Medical is proud to deliver Emrosi, a unique treatment option for the millions of patients in the U.S. suffering from rosacea,&#8221; said Claude Maraoui, co-founder, president and CEO of Journey Medical.
&#8220;Rosacea is a difficult to treat skin condition and based on the favorable results from our Phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition. Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea.&#8221;
Journey Medical said it intends to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization. The company aims to execute a launch strategy to help push Emrosi toward becoming the new oral standard of care for adult rosacea patients.
See Also:<a href="https://www.benzinga.com/general/biotech/24/11/41713478/jim-cramer-says-vertex-doing-lords-work-can-q3-earnings-outshine-bearish-charts"> Jim Cramer Says Vertex Doing &#8216;Lord&#8217;s Work&#8217;: Can Q3 Earnings Outshine Bearish Charts?</a>
DERM Price Action: <a href="http://benzinga.com/quote/derm">Journey Medical shares</a> were up 3.40% at $6.38 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

What's Going On With Journey Medical Stock Today?

Journey Medical shares are trading higher after the company announced the preparation of the U.S. launch of its FDA-approved rosacea drug Emrosi.

Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi&#x2122; (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd.
Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical, said, "With approval from the FDA, Journey Medical is proud to deliver Emrosi, a unique treatment option for the millions of patients in the U.S. suffering from rosacea. Rosacea is a difficult to treat skin condition and based on the favorable results from our Phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition. Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea. Journey Medical is committed to bringing cutting-edge innovation to patients with dermatological conditions and the healthcare professionals who treat them."
The approval of Emrosi is supported by positive data from Journey Medical's two Phase 3 clinical trials for the treatment of rosacea. The Phase 3 clinical trials met all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues. Emrosi demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea&#xAE; 40 mg capsules, and placebo for Investigator's Global Assessment treatment success as well as the reduction in total inflammatory lesion count in both studies.
Journey Medical is completing the manufacturing of Emrosi for the U.S. market and anticipates that initial supply will be available late in the first quarter or early in the second quarter of 2025. Journey Medical intends to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization. In line with the approved label, Journey Medical will execute a launch strategy to drive Emrosi toward becoming a new oral standard of care for adult rosacea patients.
Srinivas Sidgiddi, M.D., Vice President, Research &amp; Development at Journey Medical, added, "Emrosi showed great efficacy and tolerability in the pivotal clinical trials, and we are tremendously grateful to the patients, physicians, investigators, and site coordinators who participated and contributed to this important approval milestone."

Government

Regulations

Journey Medical Prepares US Launch for FDA-Approved Rosacea Drug Emrosi

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea&#xAE;) in Healthy Subjects
With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea
New Drug Application for DFD-29 under review by FDA with PDUFA goal date of November 4, 2024

Events

Journey Medical Presents DFD-29 Data At 44th Fall Clinical Dermatology Conference

Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy rating and announces Price Target of $9.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9

Rodman &amp; Renshaw initiates coverage on Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy rating and announces Price Target of $9.

Rodman & Renshaw Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9

WIIM

Journey Medical shares are trading higher after the company reported better-than-expected Q2 revenue results.

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 63.04 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $14.855 million which beat the analyst consensus estimate of $13.880 million by 7.02 percent. This is a 13.49 percent decrease over sales of $17.172 million the same period last year.

Earnings Misses

Journey Medical Q2 2024 GAAP EPS $(0.17) Misses $(0.14) Estimate, Sales $14.855M Beat $13.880M Estimate

Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy and announces $11 price target.

Roth MKM Reinstates Buy on Journey Medical, Announces $11 Price Target

Shares of Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has <a href="https://www.benzinga.com/quote/SKYE/news">discontinued the program</a>.
Skye Bioscience shares tumbled 18.9% to $8.87 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares jumped 123% to $4.3001 following the completion of the company&#8217;s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) gained 79.8% to $0.7082 after the company was awarded a sub-contract worth up to C$48 million by Thales Canada for software development services.</li>
<li>Wearable Devices Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) jumped 63% to $0.5547. Wearable Devices reported the successful completion of its first phase of integration with Qualcomm&#8217;s Snapdragon Spaces&#x2122;, extended reality (XR) Developer Platform.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) gained 45.1% to $1.0450 after declining around 8% on Friday.</li>
<li>ICC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCH#NASDAQ">ICCH</a>) jumped 43% to $22.03. Mutual Capital Group announced plans to acquire ICC Holdings, Inc. for $23.50 per share in a $73.8 million transaction.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) shares gained 32.3% to $0.5623 after jumping over 15% on Friday.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 28.6% to $283.00.</li>
<li>Renovaro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) rose 25.6% to $1.62.</li>
<li>Wetouch Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) surged 25% to $2.23.</li>
<li>Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) gained 24% to $5.83.</li>
<li>Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) surged 22% to $16.83.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) rose 20.2% to $5.33.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) gained 18% to $10.74.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) jumped 17.5% to $5.58.</li>
<li>Silynxcom Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NYSE">SYNX</a>) surged 17% to $2.62.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) jumped 16.6% to $0.4960 after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) gained 15% to $0.1070 after the company was awarded a new US patent titled &#8216;Automated Growing Systems.&#8217;</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) rose 13.6% to $0.9869. FuelCell Energy reported a second-quarter fiscal 2024 revenue decline of 42% year-over-year to $22.42 million, beating the consensus of $21.35 million.</li>
<li>Cactus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) gained 13.6% to $53.19.</li>
<li>Tellurian Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NASDAQ">TELL</a>) gained 12.8% to $0.8448.</li>
<li>SEACOR Marine Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMHI#NYSE">SMHI</a>) gained 12.1% to $13.26.</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) shares rose 10.9% to $0.0988 after surging 17% on Friday.</li>
<li>KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) gained 9.8% to $107.63 after it was announced the company will join the S&amp;P 500.</li>
<li>Diamond Offshore Drilling, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DO#NYSE">DO</a>) climbed 9.8% to $15.30 after Noble announced an agreement to acquire the company.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) gained 8.8% to $379.95 after it was announced the company will join the S&amp;P 500.</li>
<li>LENZ Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) rose 8.2% to $16.85.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) shares rose 7.6% to $3.6302 after the company said it has established a daily supply capacity of over 20 million eggs.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 7.5% to $3.01.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) gained 6.8% to $29.66 following a report indicating Elliott Investment Management has built a stake in the company.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) rose 5.9% to $4.8592. Barclays initiated coverage on Geron with an Overweight rating and announced a price target of $9.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) dipped 32.5% to $0.4828.</li>
<li>Baijiayun Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) fell 32% to $3.7001</li>
<li>Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares fell 31.4% to $0.3830.</li>
<li>Tharimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) dipped 30% to $3.6051</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) fell 29.3% to $2.3550. Tonix Pharmaceuticals recently announced a 1-for-32 reverse stock split.</li>
<li>Enservco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENSV#NYSE">ENSV</a>) fell 29.3% to $0.1713 after the company announced the staff of NYSE Regulation determined to commence proceedings to delist its common stock.</li>
<li>Perion Network Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) shares fell 28.3% to $8.84 after the company cut its revenue outlook.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 24.7% to $0.6249 after the company announced the voluntary delisting date of its ADS rights from Nasdaq.</li>
<li>SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) declined 23% to $4.22.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 19.9% to $19.62</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 16.8% to $2.66 in pre-market trading after jumping 58% on Friday.</li>
<li>Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares fell 14.8% to $1.68.</li>
<li>Trinity Place Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NYSE">TPHS</a>) fell 14.7% to $0.1498 after jumping 45% on Friday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 13.1% to $24.53. On Friday, the stock traded lower as Roaring Kitty held a live stream and the company reported Q1 earnings.</li>
<li>Golden Matrix Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMGI#NASDAQ">GMGI</a>) declined 12.5% to $3.16.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 11.8% to $16.01.</li>
<li>Anywhere Real Estate Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) fell 10.6% to $3.4150.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 10.6% to $10.11</li>
<li>BioCardia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares fell 10% to $3.35. On Friday, BioCardia announced it received approval from the United States Patent Office for its application entitled, "Radial and Transendocardial Delivery Catheter."</li>
<li>Cumulus Media Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares fell 7.6% to $2.9550 after jumping around 22% on Friday.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) fell 7.6% to $12.36. Compass Minerals International named Jeffrey Cathey as its new chief financial officer.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) fell 7% to $68.08.</li>
<li>Roma Green Finance Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) shares declined 6% to $0.4683. Roma Green Finance filed for offering in a best efforts self-underwritten offering of up to 3.6 million of ordinary shares.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39249956/flexshopper-and-3-other-stocks-under-5-insiders-are-buying">FlexShopper And 3 Other Stocks Under $5 Insiders Are Buying</a>

AGRI

AILE

CELH

CLEU

CMLS

CRWD

EFSH

ENSV

ESPR

FCEL

GERN

GMGI

HOUS

HOVR

ICCH

LENZ

MLGO

NISN

NVAX

OPRA

PERI

PRST

RENB

ROMA

SBFM

SIFY

SKYE

SMHI

SPEC

SYNX

TELL

THAR

TNXP

TPHS

VRAX

WETH

WLDS

Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.23) by 130.43 percent. The company reported quarterly sales of $13.000 million which missed the analyst consensus estimate of $14.098 million by 7.79 percent. This is a 6.44 percent increase over sales of $12.213 million the same period last year.

Journey Medical Q1 2024 Adj EPS $(0.53) Misses $(0.23) Estimate, Sales $13.000M Miss $14.098M Estimate

Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. &nbsp;
Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, said, "Joe has been an instrumental leader to our finance and accounting team for the past few years and it will be a seamless transition as he steps into the permanent CFO role. With more than 25 years of experience in the public and private sectors including the life sciences industry, Joe's in-depth financial and accounting knowledge and pharmaceutical experience are valuable assets to our company as we focus on our many upcoming milestones, including the potential approval of DFD-29 for the treatment of rosacea later this year. We look forward to Joe's continued contributions to Journey Medical."
Mr. Benesch has over 25 years of experience in all aspects of corporate financial leadership and reporting, technical accounting and controls, corporate controllership, regulatory and public company compliance, treasury and pharmaceutical company operations. Prior to joining Journey Medical, Mr. Benesch previously served as the Principal Accounting Officer, Vice President and Corporate Controller of Teligent Pharma Inc., a specialty generic pharmaceutical company, and Corporate Controller of Torrent Pharmaceuticals, a U.S. subsidiary of the Torrent Group, a multinational pharmaceutical company. Before joining Torrent, he held senior financial management positions of increasing responsibility from Corporate Controller to Vice President of Finance at Savient Pharmaceuticals, Adare Pharmaceuticals and Edenbridge Pharmaceuticals. Mr. Benesch began his career in the public accounting sector at Baker Tilly Virchow Krause, LLP, and Ernst and Young working with a diverse client base. Mr. Benesch is a graduate of Wilkes University where he earned a BA in accounting and is a Certified Public Accountant.
"I am privileged and honored to continue to lead our finance organization as we seek to drive sustainable value creation for the Company and our shareholders while helping the many patients treated with our dermatology products," said Mr. Benesch.

Journey Medical Corporation Appoints Joseph Benesch As Chief Financial Officer, Effective April 26, 2024

The Dow Jones index closed higher by over 475 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Retractable Technologies </h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvp#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/quote/RVP/analyst-ratings"> acquired a total of 5,096 shares </a> an average price of $1.18. To acquire these shares, it cost around $6,024.</li>
<li>What&rsquo;s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
<h3>Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cia#NYSE">CIA</a>) Director James Keith Morgan <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,899 shares at </a> at an average price of $2.11. To acquire these shares, it cost around $12,469.</li>
<li>What&rsquo;s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/03/37975793/walgreens-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-cal"> Walgreens Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>
<h3>Journey Medical </h3>
<ul>
<li>The Trade: Journey Medical Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/derm#NASDAQ">DERM</a>) Director Lindsay A MD Rosenwald <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 10,000 shares </a> at an average price of $3.04. The insider spent around $30,400 to buy those shares.</li>
<li>What&rsquo;s Happening: On March 21, Journey Medical posted a profit for the fourth quarter.</li>
<li>What Journey Medical Does: Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Long Ideas

Penny Stocks

Insider Trades

Journey Medical And 2 Other Stocks Under $4 Insiders Are Buying

Press Releases

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Health Care

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Comments

Journey Medical

Journey Medical (DERM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL